Simple Summary Ibrutinib is an established standard of care in the first-line treatment of
chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term …

Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the
western world. In Italy, venetoclax was approved for use in patients with CLL as …

BACKGROUND: Novel agents (NAs)(ibrutinib, idelalisib, and venetoclax) were first
introduced in 2013 as therapeutic options to treat chronic lymphocytic leukemia (CLL) …

Ibrutinib has dramatically changed the treatment landscape for chronic lymphocytic
leukemia (CLL) since its availability in British Columbia (BC), Canada in 2014. We analyzed …

Simple Summary In clinical trials, ibrutinib was found to be effective and well-tolerated in
patients with chronic lymphocytic leukemia (CLL). To confirm these findings, data on …

Simple Summary Key Objective: Why do patients with unresectable stage III non-small cell
lung cancer (NSCLC) experience durvalumab treatment initiation delays, interruptions, and …

Purpose Ibrutinib is a tyrosine kinase inhibitor that is increasingly prescribed in chronic
lymphocytic leukemia (CLL). Invasive fungal infections (IFIs) have been reported early after …

Chronic lymphocytic leukemia (CLL) is a manageable, but incurable, condition, with variable
disease course. CLL, including small lymphocytic lymphoma (SLL), is the most prevalent …

Background informCLL is the largest US-based prospective, observational registry of
patients with chronic lymphocytic leukemia (CLL) initiating FDA-approved treatment in the …

The approval of durvalumab, an immune checkpoint inhibitor, for the treatment of non-small
cell lung cancer (NSCLC) was based on the landmark PACIFIC trial and created a paradigm …